File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A Systematic Review of Potential Therapeutic Use of Lycium Barbarum Polysaccharides in Disease

TitleA Systematic Review of Potential Therapeutic Use of Lycium Barbarum Polysaccharides in Disease
Authors
Issue Date2019
PublisherHindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/jbb/index.html
Citation
BioMed Research International, 2019, v. 2019, p. 4615745:1-4615745:18 How to Cite?
AbstractObjective. To evaluate the effect of Lycium barbarum polysaccharides in the treatment and/or prevention of diseases of different etiologies and systems. Methods. We performed an Entrez PubMed literature search using keywords “lycium”, “barbarum”, “polysaccharides”, “anti-fibrotic”, “anti-apoptotic”, “anti-oxidizing”, “anti-aging”, “neuroprotection”, “metabolism”, “diabetes”, “hyperlipidemia”, “neuroprotection”, and “immunomodulation” on the 14th of August 2018, resulting in 207 papers, of which 20 were chosen after filtering for ‘English language’ and ‘published within 10 years’ as well as curation for relevance by the authors. Results. The 20 selected papers included 2 randomized control trials (1 double-blinded RCT and 1 double-blinded placebo-controlled RCT), 11 in vivo studies, 5 in vitro studies, 1 study with both in vivo and in vitro results, and 1 chemical study. There is good evidence from existing studies on the antifibrotic, antioxidizing, neuroprotective, anticancer, and anti-inflammatory effects of Lycium barbarum polysaccharides. However, there is a need for further studies in the form of large-scale clinical trials to support its use in humans. There is also significant potential for LBP as a safe and effective topical treatment in ocular surface diseases, owing to promising in vitro results and a lack of demonstrated toxic effects to corneal epithelial cells. Conclusion. Results from existing studies suggest that LBP is a promising therapeutic agent, particularly in the management of liver disease, hyperlipidemia, and diabetes. One major limitation of current research is a lack of standardization and quality control for the LBP used. The availability of research-grade LBP will inevitably promote future research in this field worldwide.
Persistent Identifierhttp://hdl.handle.net/10722/267364
ISSN
2023 Impact Factor: 2.6
2023 SCImago Journal Rankings: 0.656
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKwok, SS-
dc.contributor.authorBU, Y-
dc.contributor.authorLo, ACY-
dc.contributor.authorChan, TCY-
dc.contributor.authorSo, KF-
dc.contributor.authorLai, JSM-
dc.contributor.authorShih, KC-
dc.date.accessioned2019-02-18T09:00:31Z-
dc.date.available2019-02-18T09:00:31Z-
dc.date.issued2019-
dc.identifier.citationBioMed Research International, 2019, v. 2019, p. 4615745:1-4615745:18-
dc.identifier.issn2314-6133-
dc.identifier.urihttp://hdl.handle.net/10722/267364-
dc.description.abstractObjective. To evaluate the effect of Lycium barbarum polysaccharides in the treatment and/or prevention of diseases of different etiologies and systems. Methods. We performed an Entrez PubMed literature search using keywords “lycium”, “barbarum”, “polysaccharides”, “anti-fibrotic”, “anti-apoptotic”, “anti-oxidizing”, “anti-aging”, “neuroprotection”, “metabolism”, “diabetes”, “hyperlipidemia”, “neuroprotection”, and “immunomodulation” on the 14th of August 2018, resulting in 207 papers, of which 20 were chosen after filtering for ‘English language’ and ‘published within 10 years’ as well as curation for relevance by the authors. Results. The 20 selected papers included 2 randomized control trials (1 double-blinded RCT and 1 double-blinded placebo-controlled RCT), 11 in vivo studies, 5 in vitro studies, 1 study with both in vivo and in vitro results, and 1 chemical study. There is good evidence from existing studies on the antifibrotic, antioxidizing, neuroprotective, anticancer, and anti-inflammatory effects of Lycium barbarum polysaccharides. However, there is a need for further studies in the form of large-scale clinical trials to support its use in humans. There is also significant potential for LBP as a safe and effective topical treatment in ocular surface diseases, owing to promising in vitro results and a lack of demonstrated toxic effects to corneal epithelial cells. Conclusion. Results from existing studies suggest that LBP is a promising therapeutic agent, particularly in the management of liver disease, hyperlipidemia, and diabetes. One major limitation of current research is a lack of standardization and quality control for the LBP used. The availability of research-grade LBP will inevitably promote future research in this field worldwide.-
dc.languageeng-
dc.publisherHindawi Publishing Corporation. The Journal's web site is located at http://www.hindawi.com/journals/jbb/index.html-
dc.relation.ispartofBioMed Research International-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleA Systematic Review of Potential Therapeutic Use of Lycium Barbarum Polysaccharides in Disease-
dc.typeArticle-
dc.identifier.emailLo, ACY: amylo@hku.hk-
dc.identifier.emailSo, KF: hrmaskf@hku.hk-
dc.identifier.emailLai, JSM: laism@hku.hk-
dc.identifier.emailShih, KC: kcshih@hku.hk-
dc.identifier.authorityLo, ACY=rp00425-
dc.identifier.authoritySo, KF=rp00329-
dc.identifier.authorityLai, JSM=rp00295-
dc.identifier.authorityShih, KC=rp01374-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1155/2019/4615745-
dc.identifier.scopuseid_2-s2.0-85062344272-
dc.identifier.hkuros296981-
dc.identifier.volume2019-
dc.identifier.spage4615745:1-
dc.identifier.epage4615745:18-
dc.identifier.isiWOS:000459660500001-
dc.publisher.placeUnited States-
dc.identifier.issnl2314-6133-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats